HLA Targeting Efficiency Correlates with Human T-Cell Response Magnitude and with Mortality from Influenza A Infection T-cell responses to A/H1N1 (2009) were measured from peripheral blood mononuclear cells obtained from a household cohort study performed during the 2009-2010 influenza season. Scientists found that HLA targeting efficiency scores significantly correlated with IFN-γ enzyme-linked immunosorbent spot responses. [Proc Natl Acad Sci USA] Abstract Negative Regulation of Type I IFN Expression by OASL1 Permits Chronic Viral Infection and CD8+ T-Cell Exhaustion Researchers explored whether 2′-5′ oligoadenylate synthetase-like 1 (OASL1), a recently defined interferon (IFN)-I negative regulator, plays a key role in the virus-specific T-cell response and viral defense against chronic lymphocytic choriomeningitis virus. [PLoS Pathog] Full Article A Mouse Model for Human Norovirus The authors found that human norovirus (HuNoV) replication in BALB/c Rag-γc-deficient mice is dependent on the immune-deficient status of the host but not on the presence of human immune cells and provides the first genetically manipulable small-animal model for studying HuNoV infection. [mBio] Abstract | Press Release Human Cytomegalovirus Viral IL-10 Polarizes Monocytes towards a Deactivated M2c Phenotype to Repress Host Immune Responses Skewing of polarization towards an M2 subset may benefit a virus by limiting the pro-inflammatory responses to infection and so the authors determined whether human cytomegalovirus encoded viral interleukin (IL)-10 influenced monocyte polarization. Recombinant viral IL-10 protein polarized CD14+ monocytes towards an anti-inflammatory M2 subset with an M2c phenotype, as demonstrated by high expression of CD163 and CD14, and suppression of MHC class II. [J Virol] Abstract HIV Bispecific Antibodies Directed to CD4 Domain 2 and HIV Envelope Exhibit Exceptional Breadth and Picomolar Potency against HIV-1 Currently, no single broadly neutralizing Ab (bNAb) or combination of bNAbs neutralizes all HIV-1 strains at practically achievable concentrations in vivo. To address this problem, investigators created bispecific Abs that combine the HIV-1 inhibitory activity of ibalizumab, a humanized mAb directed to domain 2 of human CD4, with that of anti-gp120 bNAbs. [Proc Natl Acad Sci USA] Abstract Antiretroviral Therapy Initiated within Six Months of HIV Infection Is Associated with Lower T-Cell Activation and Smaller HIV Reservoir Size Researchers investigated whether very early antiretroviral therapy initiation is associated with lower on-therapy immune activation and HIV persistence. [J Infect Dis] Abstract Vaccine-Induced Gag-Specific T Cells Are Associated with Reduced Viremia after HIV Infection Scientists assessed whether vaccine-induced T-cell immunity, or expression of certain HLA alleles, impacted HIV control post-infection in the Step MRKAd5/HIV-1 gag/pol/nef Study. [J Infect Dis] Abstract CCL19 and CCL28 Augment Mucosal and Systemic Immune Responses to HIV-1 gp140 by Mobilizing Responsive Immunocytes into Secondary Lymph Nodes and Mucosal Tissue Scientists investigated whether plasmid codelivery of cytokines APRIL, CCL19, or CCL28 can enhance Ag-induced immune responses to HIV-1 gp140. Their results demonstrated that pCCL19 and pCCL28, but not pAPRIL, significantly enhanced Ag-specific systemic and mucosal Ab responses. [J Immunol] Abstract HIV-1 Vpr Modulates Macrophage Metabolic Pathways: A SILAC-Based Quantitative Analysis The authors aimed to use a stable-isotope labeling by amino acids in cell culture (SILAC) coupled with mass spectrometry-based proteomics approach to characterize the Vpr response in macrophages. Cultured human monocytic cells, U937, were differentiated into macrophages and transduced with adenovirus construct harboring the Vpr gene. [PLoS One] Full Article |